Glucose News and Research

RSS

Phase III clinical trials: Linagliptin achieves significant, sustained reductions in blood sugar

Data from four pivotal Phase III clinical trials demonstrate that linagliptin achieved statistically significant and sustained reductions in blood sugar as measured by hemoglobin A1c, fasting plasma glucose and postprandial glucose. Boehringer Ingelheim Pharmaceuticals, Inc. is investigating the dipeptidyl peptidase 4 inhibitor as an oral once-daily tablet, as monotherapy and combination therapy, to treat type 2 diabetes.

28 Jun 2010

Data on MetAP2 inhibitors for treatment of obesity presented at ADA 2010

Zafgen, Inc., a pharmaceutical company pioneering novel obesity therapeutics to help the body regain and sustain a lean, healthy state by targeting imbalances in fat metabolism, today announced data on ZGN-201, a prototype methionine aminopeptidase 2 inhibitor, for the treatment of obesity. Preclinical studies demonstrate MetAP2 inhibition eliminates excess body weight through the regulation of fat metabolism and food intake, and normalizes glucose tolerance in animal models.

28 Jun 2010

Researchers discover genetic links to kidney failure, diabetic kidney disease

Researchers at the Translational Genomics Research Institute will make two presentations at this week's 70th Scientific Sessions of the American Diabetes Association, June 25-29, in Orlando, Florida.

28 Jun 2010

New preclinical data of XOMA 052 in animal model of Type 2 diabetes to be presented at ADA 2010

XOMA Ltd., a leader in the discovery and development of therapeutic antibodies, will be presenting new preclinical data in an animal model of Type 2 diabetes in which its anti-inflammatory therapeutic antibody candidate, XOMA 052, was used as monotherapy and in combination with the marketed anti-diabetic drugs exendin-4 (Byetta) or sitagliptin (Januvia).

28 Jun 2010

Data shows Victoza produces greater reductions in A1c, body weight and FPG than Januvia

Late-breaking Novo Nordisk extension data presented today at the 70th Annual Scientific Sessions of the American Diabetes Association showed that once-daily Victoza in combination with metformin produced sustained and significantly greater reductions in A1c, body weight and fasting plasma glucose than Januvia plus metformin at 52 weeks.

28 Jun 2010

Phase 2b clinical trial data of SGLT2 inhibitor in patients with type 2 diabetes presented at ADA 2010

Johnson & Johnson Pharmaceutical Research & Development, L.L.C. announced today that canagliflozin, an investigational, oral, selective sodium-glucose transporter-2 inhibitor, improved glycemic control, and was also associated with a decrease in body weight, in a Phase 2b dose-ranging trial in patients diagnosed with type 2 diabetes who were concurrently treated with metformin. The data were presented at the 70th American Diabetes Association Scientific Sessions.

28 Jun 2010

Surgical care improvement measures associated with lower probability of postoperative infection: JAMA

An analysis of data on adherence to surgical care improvement measures finds that when analyzed as a composite infection-prevention score, the improvement measures were associated with a lower probability of postoperative infection. However, adherence to individual measures - the format of publicly reported performance data - was not associated with a significantly lower risk of infection, according to a study in the June 23/30 issue of JAMA.

25 Jun 2010

NKI awarded Phase II SBIR grant to develop new ophthalmic screening device for diabetic retinopathy

Neuro Kinetics, Inc., manufacturers of noninvasive medical diagnostic equipment used worldwide to test for vestibular and neurological conditions, said today that it has been awarded a Phase II Small Business Innovation Research grant to further the company's development of a new ophthalmic screening device and testing protocols for the detection and diagnosis of diabetic retinopathy.

25 Jun 2010

Abbott's new FreeStyle test strips receive FDA clearance

Following the recent clearance of its FreeStyle Lite® blood glucose test strips, Abbott (NYSE: ABT) today announced that it has also received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its new FreeStyle blood glucose test strips.

25 Jun 2010

MDS Nordion, Guerbet, Cyceron collaborate to develop new PET radiotracers for cancer diagnostics

MDS Nordion, a leading provider of products and services to the global health science market, Guerbet, a pharmaceutical group specialized in medical imaging, and Cyceron, a biomedical imaging centre in France, announced today they have entered into an agreement to develop new Positron Emission Tomography (PET) radiotracers for cancer diagnostics.

24 Jun 2010

Patient health and safety initiatives to be highlighted at ADA annual conference

Roche Diabetes Care, makers of the ACCU-CHEK portfolio of diabetes management products and services, will highlight leading patient health and safety initiatives during the 70th annual American Diabetes Association Annual Conference June 26-28 in Orlando, FL.

From Roche Sequencing and Life Science 24 Jun 2010

Study examines relationship between SCIP measures and postoperative infection

A study by investigators at Case Western Reserve University School of Medicine published in this week's issue of JAMA found that public hospital comparison data reported by the U.S. Department of Health and Human Services does not accurately correlate with a patient's risk for surgical postoperative infection.

24 Jun 2010

Spherix to explore triglycerides for D-tagatose therapy

Spherix Incorporated, an innovator in biotechnology for diabetes therapy, and a provider of technical and regulatory consulting services to food, supplement, biotechnology and pharmaceutical companies, today announced that it will explore triglycerides as a potential therapeutic opportunity for its D-tagatose therapy, pending a review of data from a Phase 3 clinical trial the Company is conducting on the use of D-tagatose as a treatment for Type 2 diabetes.

24 Jun 2010

Dapagliflozin as monotherapy demonstrates potential for type 2 diabetes treatment

Findings from a 24-week Phase 3 clinical study published online in the latest issue of Diabetes Care demonstrated that the investigational drug dapagliflozin, administered as a monotherapy, achieved statistically significant mean reductions at 5 mg and 10 mg doses once daily in the primary endpoint of glycosylated hemoglobin levels (HbA1c) in treatment-naïve adult patients with newly diagnosed type 2 diabetes, compared to placebo.

23 Jun 2010

High blood sugar in mother during pregnancy leads to reduced insulin sensitivity in children

Children of mothers whose blood glucose (sugar) was high during pregnancy are more likely to have low insulin sensitivity—a risk factor for type 2 diabetes—even after taking into consideration the children's body weight, a new study shows. The results will be presented Tuesday at The Endocrine Society's 92nd Annual Meeting in San Diego.

23 Jun 2010

Weight gain after age of 50 is associated with increased risk of diabetes after 65 years

For individuals 65 years of age and older, obesity, excess body fat around the waist and gaining weight after the age of 50 are associated with an increased risk of diabetes, according to a study in the June 23/30 issue of JAMA.

23 Jun 2010

Walmart, Eli Lilly to provide affordable insulin option for people with diabetes

Walmart and Eli Lilly and Company announced today they're teaming up to provide an affordable insulin option for people with diabetes.

23 Jun 2010

Mice treated with XOMA 052 experiences improvement in measures associated with diabetes: Endocrinology

XOMA Ltd., a leader in the discovery and development of therapeutic antibodies, announced the publication of data from a mouse model of diet-induced obesity in the June, 2010 edition of the journal Endocrinology. The data showed that mice treated with XOMA 052 both prophylactically and therapeutically experienced improvement in measures associated with diabetes and cardiovascular disease including reduction in glycosylated hemoglobin levels, improvement in glucose control, improved beta-cell survival and function, and a reduction in total cholesterol without reduction in high density lipoprotein.

23 Jun 2010

Fructose makes cells mature into fat cells in belly fat, study finds

Fructose, the sugar widely used as high-fructose corn syrup in soft drinks and processed foods, often gets some of the blame for the widespread rise in obesity. Now a laboratory study has found that when fructose is present as children's fat cells mature, it makes more of these cells mature into fat cells in belly fat and less able to respond to insulin in both belly fat and fat located below the skin.

22 Jun 2010

Diabetic individuals living in hot climate need increased 'heat awareness'

A new survey shows that diabetic individuals who live in a hot climate have important gaps in their "heat awareness," or knowledge about proper diabetes self-care in hot weather, even though diabetes raises their risk of heat illness. The results of "Diabetes in the Desert: What Do Patients Know About the Heat?" will be presented Monday at The Endocrine Society's 92nd Annual Meeting in San Diego.

22 Jun 2010

Glucose News and Research

Phase III clinical trials: Linagliptin achieves significant, sustained reductions in blood sugar

Data on MetAP2 inhibitors for treatment of obesity presented at ADA 2010

Researchers discover genetic links to kidney failure, diabetic kidney disease

New preclinical data of XOMA 052 in animal model of Type 2 diabetes to be presented at ADA 2010

Data shows Victoza produces greater reductions in A1c, body weight and FPG than Januvia

Phase 2b clinical trial data of SGLT2 inhibitor in patients with type 2 diabetes presented at ADA 2010

Surgical care improvement measures associated with lower probability of postoperative infection: JAMA

NKI awarded Phase II SBIR grant to develop new ophthalmic screening device for diabetic retinopathy

Abbott's new FreeStyle test strips receive FDA clearance

MDS Nordion, Guerbet, Cyceron collaborate to develop new PET radiotracers for cancer diagnostics

Patient health and safety initiatives to be highlighted at ADA annual conference

Study examines relationship between SCIP measures and postoperative infection

Spherix to explore triglycerides for D-tagatose therapy

Dapagliflozin as monotherapy demonstrates potential for type 2 diabetes treatment

High blood sugar in mother during pregnancy leads to reduced insulin sensitivity in children

Weight gain after age of 50 is associated with increased risk of diabetes after 65 years

Walmart, Eli Lilly to provide affordable insulin option for people with diabetes

Mice treated with XOMA 052 experiences improvement in measures associated with diabetes: Endocrinology

Fructose makes cells mature into fat cells in belly fat, study finds

Diabetic individuals living in hot climate need increased 'heat awareness'

Discover how SciY empowers scientists

Why use light scattering to analyze proteins and viral vectors?

Changing the landscape of R&D to build clinical success from the ground up

Latest News